No Data
China Resources Sanjiu Medical & Pharmaceutical (000999.SZ): In 2024, the company is expected to exceed the industry average growth rate in revenue.
Gelonghui October 10th | China Resources Sanjiu Medical & Pharmaceutical (000999.SZ) stated at an investor relations event that looking ahead for the whole year, changes in incidence rates, implementation of certain industry policies, and changes in the external environment may bring certain uncertainties to the company's operations, for which the company has formulated specific response measures. In 2024, the company expects revenue to surpass the industry's average growth rate, striving to achieve a double-digit growth target, matching the corresponding reasonable profit growth rate.
China Resources Sanjiu Medical & Pharmaceutical (000999.SZ): Prescription-free flow is a long-term trend, expected to bring long-term incremental growth and opportunities to the retail market.
Gelonghui October 10th | China Resources Sanjiu Medical & Pharmaceutical (000999.SZ) stated at an investor relations event that medical insurance policies are driving the industry towards high-quality development. The outflow of prescriptions is a long-term trend that is expected to bring long-term growth opportunities to the retail market. The outpatient market is also an important part of the market, crucial to our business. The company pays high attention to market dynamics, conducts specialized research, implements response measures, and actively seizes future development opportunities.
China Resources Sanjiu Medical & Pharmaceutical (000999.SZ): The company is paying attention to relevant policies and actively communicating during the consultation period.
On October 10th, China Resources Sanjiu Medical & Pharmaceutical (000999.SZ) stated at an investor relations event that the company has noted the notice published on September 9th regarding the "Solicitation of Opinions on the Anhui Province's 2024 Chinese Patent Medicine Centralized Volume-based Purchasing Document (Draft for Solicitation of Opinions)". Ganmaoling is not included in the national medical insurance catalog, and the company's Ganmaoling product focuses on the OTC market, allowing consumers to choose to purchase it independently, establishing a "warm and caring" brand reputation in the minds of consumers. Currently, the company believes that this notice has extremely limited impact on Ganmaoling in the cold product category. In the future, Ganmaoling will continue to
china resources sanjiu medical & pharmaceutical (000999.SZ): The overall channel inventory generally stays at around 2.5-3 months.
Gelonghui October 10th | China Resources Sanjiu Medical & Pharmaceutical (000999.SZ) stated at an investor relations event that the company's core categories such as cold medicine have a good channel inventory situation. Over the past year, the sales of cold products have been strong, which has put some pressure on production capacity, resulting in relatively low channel inventory levels. Overall channel inventory levels are generally around 2.5-3 months.
China Resources Sanjiu Medical & Pharmaceutical (000999.SZ): It is more likely that the gross margin of the CHC business will fluctuate within a reasonable range in the future.
On October 10th, Cailian Press reported that China Resources Sanjiu Medical & Pharmaceutical (000999.SZ) stated during an investor relations event that the increase in gross margin of the CHC business in the first half of the year was mainly a financial result of changes in business combinations, which may not necessarily represent operational trends. The company's CHC business aims to achieve overall layout and comprehensive leadership, striving to emerge victorious in a wide range of product categories. Changes in gross margin may be influenced by seasonal variations and an increase in the proportion of high-margin products. It is more likely that the gross margin of CHC business will fluctuate within a reasonable range in the future.
China Resources Sanjiu Medical & Pharmaceutical (SZSE:000999) Jumps 21% This Week, Though Earnings Growth Is Still Tracking Behind Three-year Shareholder Returns
China Resources Sanjiu Medical & Pharmaceutical's (SZSE:000999) Investors Will Be Pleased With Their Strong 123% Return Over the Last Three YearsNo Data
No Data
